MedTrace Logo

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

NCT02406222 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2024-12-05

No results posted yet for this study

Summary

This study is determining whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression free survival in patients with relapsed refractory myeloma (RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1 basis to receive CPD or Pd. Treatment will be continued until disease progression or unacceptable toxicity.

Conditions

Interventions

DRUG

Pomalidomide

Chemotherapy

DRUG

Dexamethasone

Chemotherapy

DRUG

Cyclophosphamide

Chemotherapy

Sponsors & Collaborators

  • Myeloma UK

    collaborator OTHER

  • Celgene

    collaborator INDUSTRY

  • University of Leeds

    lead OTHER

Principal Investigators

  • Martin Kaiser, Dr · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2022-12-31
Completion
2025-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02406222 on ClinicalTrials.gov